01—Abstract
Summary
Summary of the 8-K filed May 5, 2026. Cited figures are marked; the original filing is the authoritative source.
IDEXX Laboratories reported first-quarter 2026 results on May 5, 2026, with revenue of $1,141 milliona, up 14% as reported and 11% organic.
Growth was led by Companion Animal Group (CAG), which grew 15%b as reported and 12% organic, and CAG Diagnostics recurring revenue, which grew 14% reported and 11% organic. International recurring revenue grew 21% reported and 12% organic, while U.S. recurring revenue grew 11%, which management says outpaced sector growth. Management attributed the U.S. strength partly to a modest easing of clinical visit pressure and higher diagnostic frequency.
Reported diluted EPS was $3.47c, up 17% (15% on a comparable basis). Operating margin was 31.8%, up 10 bps as reported and 100 bps on a comparable basis, though operating expenses rose 17% as reported, reflecting commercial, R&D, and software investment. Gross margin improved 90 bps to 63.4%.
Management raised 2026 guidance. Revenue is now $4,675d-$4,760 million (8.6%-10.6% reported growth, 7.7%-9.7% organic), up about $42 million at the midpoint. The EPS outlook rose to $14.45-$14.90, with the midpoint up $0.13 from operations and $0.05 from FX, partly offset by a $0.05 loss on an equity investment.
The reported operating margin outlook is 32.1%-32.5%. Foreign currency is a meaningful tailwind, adding about 0.9% to revenue growth and about $0.27 to EPS for 2026. CEO Jay Mazelsky is transitioning out of the role, with Mike Erickson named as the successor partner; the filing does not detail the leadership change beyond the release's comments.
For investors, the quarter shows broad-based double-digit organic growth, driven by IDEXX VetLab consumables (15% organic), premium instrument installed base growth (12%), and early adoption of the IDEXX inVue Dx analyzer (about 1,100 placements). The main watch items are the CEO transition, the pace of U.S. clinical visit recovery, operating expense growth that outpaces revenue, and the rising use of debt to fund buybacks, with the line of credit increasing to $530 million from $398 million at year-end 2025.
02—Key points
Key Highlights
- Q1 2026 revenue of $1,141M grew 14% as reported and 11% organic; CAG Diagnostics recurring revenue grew 14% reported and 11% organic.
- Diluted EPS of $3.47 rose 17% as reported and 15% comparable, including a $0.14 currency benefit, a $0.09 share-based compensation tax benefit, and a $0.05 loss on an equity investment.
- Gross margin expanded 90 bps to 63.4%, and comparable operating margin expanded 100 bps to 31.8%, though operating expenses rose 17% as reported.
- 2026 revenue guidance raised to $4,675M-$4,760M (about +$42M at midpoint); EPS guidance raised to $14.45-$14.90, with the midpoint up $0.13 from operations and $0.05 from FX.
- Reported 2026 operating margin outlook raised to 32.1%-32.5%; free cash flow conversion target maintained at 85%-95% of net income.
- International CAG Diagnostics recurring revenue grew 21% reported and 12% organic; U.S. grew 11%, which management says outpaced the sector.
- CEO Jay Mazelsky is transitioning out of the CEO role, with Mike Erickson named as the continuing partner for long-term growth.
03—Questions
Frequently Asked Questions
Why did IDEXX raise its 2026 guidance?
Management cited strong CAG Diagnostics recurring revenue performance, an improving outlook for U.S. clinical visit trends, and operational benefits in Q1. The revenue midpoint rose about $42 million, and the EPS midpoint rose $0.13 from operations and $0.05 from updated foreign exchange assumptions, partly offset by a $0.05 equity investment loss.
How much of the Q1 growth came from currency versus the underlying business?
Currency added about 3.1 points to total revenue growth (14.3% reported vs. 11.2% organic). Currency also contributed $0.14 to Q1 EPS, and about 4.6 points to comparable EPS growth. Organic growth of 11% still shows strong underlying demand, particularly in VetLab consumables (15% organic).
Are there concerns about operating expenses or margins?
Operating expenses rose 17% as reported and 11% on a comparable basis, driven by commercial capability investments, higher R&D, software investment, and employee incentive costs. Q1 operating margin still rose 100 bps on a comparable basis, and management raised its full-year reported operating margin outlook, but continued expense growth is a key area to monitor.
What is the status of the leadership transition and the new products?
CEO Jay Mazelsky stated he is transitioning from the CEO role and will continue working with Mike Erickson on long-term growth. On products, the IDEXX Cancer Dx platform is growing with a recent international launch, and IDEXX inVue Dx had about 1,100 placements in Q1, with a controlled launch of Fine Needle Aspiration (FNA) and broader access planned for the rest of 2026.
How is the balance sheet changing?
Cash rose to $200.5M from $180.1M at year-end. The line of credit increased to $530M from $398M, and total debt (current and long-term) was about $680M, up from about $473M. The increase funded share repurchases of $351M in Q1 (versus $401M a year earlier) and capital spending. Free cash flow was $234M, up 13% year over year.
04—Continue